High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow

Cellular Oncology

Volumn 34, Issue 4, 2011, Pages 289-296

  Weidenaar, Alida C ^a   Ter Elst, Arja ^a   Koopmans Klein, Gineke ^a   Rosati, Stefano ^a   Den Dunnen, Wilfred F A ^a   Meeuwsen De Boer, Tiny ^a   Kamps, Willem A ^a   Vellenga, Edo ^a   De Bont, Eveline S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acute Myeloid Leukemia; Angiogenesis; VEGFA; Vessel morphology

Indexed keywords

BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; SMOOTH MUSCLE ACTIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PARAMETERS; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REMISSION; SURFACE PROPERTY; TUMOR VASCULARIZATION; ADOLESCENT; ANIMAL; BLOOD VESSEL; BONE MARROW; HYPERPLASIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PERICYTE; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOOD VESSELS; BONE MARROW; FEMALE; HUMANS; HYPERPLASIA; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; PERICYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84865333261     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0017-9     Document Type: Article

References (25)

1. A. Aguayo, E. Estey, H. Kantarjian, T. Mansouri, C. Gidel, M. Keating, F. Giles, Z. Estrov, B. Barlogie, M. Albitar, Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94, 3717-3721 (1999)
2. J.W. Baish, R.K. Jain, Fractals and cancer. Cancer Res. 60, 3683-3688 (2000) (Pubitemid 32204551)
3. J.C. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, D.C. Arthur, M.J. Pettenati, S.R. Patil, K.W. Rao, M.S. Watson, P. R. Koduru, J.O. Moore, R.M. Stone, R.J. Mayer, E.J. Feldman, F. R. Davey, C.A. Schiffer, R.A. Larson, C.D. Bloomfield, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from cancer to leukemia group B (CALGB 8461). Blood 100, 4325-4336 (2002) (Pubitemid 35429670)
4. D.J. Crocker, T.M. Murad, J.C. Geer, Role of the pericyte in wound healing. An ultrastructural study. Exp. Mol. Pathol. 13, 51-65 (1970)
5. E.S. de Bont, S. Rosati, S. Jacobs, W.A. Kamps, E. Vellenga, Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor. Br. J. Haematol. 113, 296-304 (2001) (Pubitemid 32523131)
6. H.J. de Jonge, E.S. de Bont, P.J. Valk, J.J. Schuringa, M. Kies, C. M. Woolthuis, R. Delwel, N.J. Veeger, E. Vellenga, B. Lowenberg, G. Huls, AML at older age: Age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 114, 2869-2877 (2009)
7. W.H. Dokter, L. Tuyt, S.J. Sierdsema, M.T. Esselink, E Vellenga, The spontaneous expression of interleukin-1β and interleukin-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia (Baltimore) 9, 425-432 (1995)
8. H.F. Dvorak, Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002) (Pubitemid 35266299)
9. W. Fiedler, R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O.G. Ottmann, W. Jung, F. Cavalli, R. Kuse, J. Thomalla, H. Serve, A.M. O'Farrell, M. Jacobs, N.M. Brega, P. Scigalla, D.K. Hossfeld, W.E. Berdel, A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102, 2763-2767 (2003) (Pubitemid 37248845)
10. J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995)
11. J. Folkman, Angiogenesis and apoptosis. Semin. Cancer Biol. 13, 159-167 (2003) (Pubitemid 36315933)
12. D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C.J. Harrison, K. Wheatley, A.K. Burnett, A.H. Goldstone, The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320 (2001)
13. I. Helfrich, I. Scheffrahn, S. Bartling, J. Weis, V. von Felbert, M. Middleton, M. Kato, S. Ergun, D. Schadendorf, Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 207, 491-503 (2010)
14. H.A. Hou, T.T. Shih, C.Y. Liu, B.B. Chen, J.L. Tang, M. Yao, S.Y. Huang, W.C. Chou, C.Y. Hsu, H.F. Tien, Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica 95, 1420-1424 (2010)
15. T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D.D. Hu-Lowe, D.R. Shalinsky, G. Thurston, G.D. Yancopoulos, D.M. McDonald, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004) (Pubitemid 38821812)
16. R.K. Jain, The next frontier of molecular medicine: Delivery of therapeutics. Nat. Med. 4, 655-657 (1998) (Pubitemid 28274655)
17. R.K. Jain, Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005) (Pubitemid 40093472)
18. J.E. Karp, I. Gojo, R. Pili, C.D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, J. Zwiebel, Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 10, 3577-3585 (2004) (Pubitemid 38697590)
19. C. Kut, F. Mac Gabhann, A.S. Popel, Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer 97, 978-985 (2007) (Pubitemid 47519292)
20. S. Lee, S.M. Jilani, G.V. Nikolova, D. Carpizo, M.L. Iruela-Arispe, Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169, 681-691 (2005) (Pubitemid 41002860)
21. T. Padro, S. Ruiz, R. Bieker, H. Burger, M. Steins, J. Kienast, T. Buchner, W.E. Berdel, R.M. Mesters, Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95, 2637-2644 (2000) (Pubitemid 30210544)
22. M. Sie, E.S. de Bont, F.J. Scherpen, E.W. Hoving, W.F. den Dunnen, Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?, Neuropathol. Appl. Neurobiol. (2010)
23. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, R.K. Jain, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004) (Pubitemid 38697278)
24. P.B. Vermeulen, G. Gasparini, S.B. Fox, C. Colpaert, L.P. Marson, M. Gion, J.A. Belien, R.M. de Waal, E. Van Marck, E. Magnani, N. Weidner, A.L. Harris, L.Y. Dirix, Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38, 1564-1579 (2002) (Pubitemid 34876495)
25. F. Yuan, Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara, R.K. Jain, Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765-14770 (1996) (Pubitemid 26419043)